HAVN Life Sciences Inc.
HAVLF · OTC
1/31/2023 | 10/31/2022 | 7/31/2022 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.00 | -0.00 |
| FCF Yield | 55.93% | -74.10% | -401.38% | -15.74% |
| EV / EBITDA | -0.77 | -1.75 | -0.74 | -0.76 |
| Quality | ||||
| ROIC | -86.84% | -100.22% | 284.68% | 33.86% |
| Gross Margin | 690.92% | 64.12% | 32.44% | 31.46% |
| Cash Conversion Ratio | -0.42 | -2.23 | 0.23 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | 837,185.26% | 853,545.70% | 694,426.01% | 651,354.73% |
| Free Cash Flow Growth | 151.81% | 37.33% | 38.58% | 0.88% |
| Safety | ||||
| Net Debt / EBITDA | -0.02 | -0.50 | -0.50 | 0.06 |
| Interest Coverage | -375,191.50 | 0.00 | -66.07 | 78.54 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 0.11 | 0.00 | 0.13 |
| Cash Conversion Cycle | -1,284.46 | 729.63 | -767.71 | 565.15 |